Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Dermatology · Cutaneous Lupus Erythematosus

Are There Non-Steroid Creams for Cutaneous Lupus?

At a Glance

Topical calcineurin inhibitors (TCIs) like tacrolimus and pimecrolimus are highly effective, non-steroid prescription creams for cutaneous lupus. They calm local skin inflammation and clear rashes without causing the skin thinning associated with long-term steroid use.

In this answer

4 sections

01

How Calcineurin Inhibitors Work

02

The “Steroid-Sparing” Advantage

03

Efficacy and Usage

04

What to Expect: Side Effects

Yes, there are highly effective prescription creams available that do not contain steroids. The most common alternatives are topical calcineurin inhibitors (TCIs), which include tacrolimus (often sold as Protopic ointment) and pimecrolimus (Elidel cream). These medications are frequently used as “steroid-sparing” treatments for rare forms of cutaneous lupus erythematosus, including Lupus Erythematosus Tumidus (LET) and Chilblain Lupus Erythematosus (CHLE) [1][2].

How Calcineurin Inhibitors Work

When you have skin lupus, your immune system mistakenly attacks healthy skin tissue, causing inflammation, redness, and lesions. Calcineurin inhibitors work by blocking a specific protein (calcineurin) in your white blood cells, which prevents them from releasing the inflammatory chemicals that cause lupus flares [1]. Because they calm the local immune response directly at the site of the rash, they can effectively reduce lupus activity without suppressing your entire body’s immune system [3].

The “Steroid-Sparing” Advantage

While topical corticosteroids are the standard first-line treatment for managing lupus rashes [4][5], using them for long periods can lead to long-lasting, difficult-to-reverse skin changes. The most significant concern for patients is atrophy (thinning of the skin) and telangiectasia (the appearance of tiny, visible blood vessels).

This is where calcineurin inhibitors shine. Because they do not contain steroids, they do not cause skin thinning [6][7]. They are considered safe for long-term use and are especially valuable for treating delicate areas where skin thins quickly, such as the face, neck, and skin folds. In fact, research shows that switching to a TCI like pimecrolimus may actually help reverse the skin thinning and visible blood vessels previously caused by long-term steroid use [8].

Efficacy and Usage

Studies show that topical tacrolimus ointment is highly effective for improving clinical symptoms across various forms of cutaneous lupus [1][9].

  • Effectiveness: Research indicates that 0.1% tacrolimus ointment can be just as effective as potent steroid creams in treating certain lupus lesions, though steroids might still be preferred for very thick, scaly patches [10][11]. It may take a few weeks of consistent use to see visible improvement in your lesions, so patience is key.
  • Combined Therapy: Your doctor might prescribe a TCI alongside a topical steroid [9]. A common strategy is to use a steroid cream to quickly bring a severe flare under control, and then switch to a TCI for long-term maintenance.
  • Sun Protection: Since forms of skin lupus like LET are triggered by UV light, daily sun protection is critical. When applying your treatments, apply the TCI first, wait about 15 to 20 minutes for it to absorb, and then apply a broad-spectrum sunscreen over the area.

What to Expect: Side Effects

The safety profile of these medications makes them an excellent option [2], but there are a few important things you should know about.

  • The “TCI Burn”: When you first start applying tacrolimus or pimecrolimus, you will likely experience a localized burning, stinging, or itching sensation at the application site [12][13][14]. This is common and generally harmless. It typically resolves on its own after a few days as your skin adjusts to the medication.
  • FDA Black Box Warning: You will notice a serious warning label (an FDA “Black Box” warning) on these medications regarding theoretical long-term risks of skin cancer and lymphoma. This warning was originally based on animal studies with very high doses and systemic (oral) administration. However, comprehensive, long-term human studies on patients using these creams topically for inflammatory skin conditions have shown that they do not significantly increase the risk of skin cancer or lymphoma [15][16].

Common questions in this guide

How do calcineurin inhibitors like tacrolimus work for skin lupus?
Topical calcineurin inhibitors are non-steroid prescription creams used to treat skin inflammation. They work by blocking a specific protein in your white blood cells, preventing them from releasing the inflammatory chemicals that cause lupus flares.
Why would my doctor prescribe tacrolimus instead of a steroid cream?
Unlike topical steroids, tacrolimus and pimecrolimus do not cause skin thinning or permanent visible blood vessels, even with long-term use. This makes them especially valuable for treating delicate areas where skin thins quickly, such as the face, neck, and skin folds.
Is it normal for my skin to burn when applying tacrolimus or pimecrolimus?
Yes, it is very common to experience a localized burning, stinging, or itching sensation when you first start applying these creams. This is generally harmless and typically goes away on its own after a few days as your skin adjusts to the medication.
Do topical calcineurin inhibitors cause cancer?
While these medications have an FDA warning based on high-dose animal studies, comprehensive, long-term human studies show they do not significantly increase the risk of skin cancer or lymphoma when used topically for skin conditions.
Can I use tacrolimus and topical steroids at the same time?
Yes, your doctor might recommend using both. A common strategy is to use a potent steroid cream to quickly bring a severe flare under control, and then switch to a non-steroid cream like tacrolimus for long-term maintenance.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given the specific locations of my rashes (e.g., face, chest, or hands), would tacrolimus ointment or pimecrolimus cream be a better fit for me?
  2. 2.How should I incorporate a topical calcineurin inhibitor into my current routine with topical steroids? Should I alternate them, or switch completely?
  3. 3.If I experience severe or prolonged burning from the medication, at what point should I stop using it and contact your office?
  4. 4.How long should I consistently use the medication before we evaluate whether it is effectively controlling my lesions?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

What is the Best Sunscreen for Lupus Tumidus (LET)?Bullous Lupus Flare: Are My Internal Organs Affected?Mouth Blisters: Are They Bullous Lupus or Pemphigus?How Should I Dress for Chilblain Lupus in Winter?What Blood Tests Are Required During Dapsone Therapy?Lupus Profundus vs. Lipoma: How Do They Differ?Lupus Tumidus vs Jessner's: What is the Difference?Can Blood Pressure Medicines Help Chilblain Lupus?When to Get Fat Grafting for Lupus Profundus Lipoatrophy?

References

References (16)
  1. 1

    Efficacy and safety of calcineurin inhibitors in cutaneous lupus: a systematic review and brief meta-analysis of recommended concentration, type, and outcomes.

    Alshathri AH, Abdellatif RA, Alshathri AH, et al.

    Annals of medicine and surgery (2012) 2025; (87(5)):2880-2888 doi:10.1097/MS9.0000000000003047.

    PMID: 40337382
  2. 2

    Usage of Topical Calcineurin Inhibitors in the Medicare Population from 2013 to 2018.

    Learned C, Alsukait S, Rosmarin D

    Journal of drugs in dermatology : JDD 2022; (21(8)):912-913 doi:10.36849/JDD.6706.

    PMID: 35946970
  3. 3

    Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.

    Guenther L, Lynde C, Poulin Y

    Journal of cutaneous medicine and surgery 2019; (23(4_suppl)):27S-34S doi:10.1177/1203475419857668.

    PMID: 31476936
  4. 4

    Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab - a case report.

    Fietz S, Fröhlich A, Mauch C, et al.

    Frontiers in immunology 2023; (14()):1324231 doi:10.3389/fimmu.2023.1324231.

    PMID: 38143738
  5. 5

    Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.

    Kosche C, Owen JL, Choi JN

    Dermatology online journal 2019; (25(10)).

    PMID: 31735010
  6. 6

    Dermatologists' Perceptions and Factors Influencing the Selection of Topical Anti-Inflammatory Agents for Atopic Dermatitis in China: A Cross-Sectional Survey Study.

    Hu J, Jia Q, Zhang W, et al.

    Clinical, cosmetic and investigational dermatology 2024; (17()):2713-2723 doi:10.2147/CCID.S487996.

    PMID: 39624065
  7. 7

    Topische Calcineurininhibitoren und das Risiko für Lymphome: eine systematische Übersicht und Metaanalyse.

    Wu PC, Huang IH, Liu CW, Huang YC

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2021; (19(9)):1265-1270 doi:10.1111/ddg.14527_g.

    PMID: 34541794
  8. 8

    Corticosteroid-induced skin damage improved with pimecrolimus cream 1% treatment: a 1-year study in adults with mild to moderate atopic dermatitis.

    Thaçi D, Bräutigam M, Luger T

    The Journal of dermatological treatment 2025; (36(1)):2493931 doi:10.1080/09546634.2025.2493931.

    PMID: 40539960
  9. 9

    Linear cutaneous lupus erythematosus in children-report of two cases and review of the literature: A case report.

    Lim D, Hatami A, Kokta V, Piram M

    SAGE open medical case reports 2020; (8()):2050313X20979206 doi:10.1177/2050313X20979206.

    PMID: 33343900
  10. 10

    Comparison of effectiveness of topical tacrolimus 0.1% vs topical halobetasol propionate 0.05% as an add-on to oral hydroxychloroquine in discoid lupus erythematosus.

    Barua DP, Chowdhury MIH, Mowla MR, et al.

    Dermatologic therapy 2021; (34(1)):e14675 doi:10.1111/dth.14675.

    PMID: 33320408
  11. 11

    Treatment of Scarring Alopecia in Discoid Variant of Chronic Cutaneous Lupus Erythematosus With Tacrolimus Lotion, 0.3.

    Milam EC, Ramachandran S, Franks AG

    JAMA dermatology 2015; (151(10)):1113-6 doi:10.1001/jamadermatol.2015.1349.

    PMID: 26039539
  12. 12

    Safety and Efficacy of Tacrolimus Ointment Alone in the Treatment of Pediatric Vitiligo: A Systematic Review and Meta-Analysis.

    Alshaikh AA, Alshaikh JA, Alatawi H

    Biomedicine hub 2025; (10(1)):33-43 doi:10.1159/000543311.

    PMID: 39906121
  13. 13

    Pimecrolimus for the Treatment of Atopic Dermatitis in Infants: An Asian Perspective.

    Chu CY, Yao TC, Shih IH, et al.

    Dermatology and therapy 2023; (13(3)):717-727 doi:10.1007/s13555-022-00886-9.

    PMID: 36735214
  14. 14

    Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience.

    Broeders JA, Ahmed Ali U, Fischer G

    Journal of the American Academy of Dermatology 2016; (75(2)):410-419.e3.

    PMID: 27177441
  15. 15

    Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis.

    Devasenapathy N, Chu A, Wong M, et al.

    The Lancet. Child & adolescent health 2023; (7(1)):13-25 doi:10.1016/S2352-4642(22)00283-8.

    PMID: 36370744
  16. 16

    Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE).

    Arana A, Pottegård A, Kuiper JG, et al.

    Clinical epidemiology 2021; (13()):1141-1153 doi:10.2147/CLEP.S331287.

    PMID: 35002327

This page provides educational information about non-steroid topical treatments for cutaneous lupus. Always consult your prescribing doctor or dermatologist before altering your lupus medication routine.

Get notified when new evidence is published on Rare cutaneous lupus erythematosus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.